Pre-Transplant Purging and Post-Transplant MRD-Guided Maintenance Therapy with Elranatamab in Patients with High-Risk Multiple Myeloma

Inclusion Criteria

• Transplant eligible patients with newly diagnosed multiple myeloma (NDMM)
• High-risk multiple myeloma. * Definition of high-risk and ultra-high-risk MM: ** High-risk MM: *** Presence of a high-risk chromosomal abnormality (HRCA) including: 17p13 deletion; t(4;14); t(14;16); t(14;20); gain or amplification 1q by fluorescence in situ hybridization (FISH) ** Ultra-high-risk MM *** Presence of ≥ 2 HRCA
• Patient with disease response ≥ partial response (PR) to induction therapy
• Age ≥ 18 and ≤ 75. Non-English-speaking patients are eligible
• Karnofsky performance status ≥ 70
• Total bilirubin ≤ 1.5 X upper limit of normal (ULN)
• Alanine aminotransferase (ALT) ≤ 2.5 X ULN
• Estimated creatinine clearance ≥ 40 mL/min. Creatinine clearance may be calculated using Cockcroft-Gault, estimated glomerular filtration rate (Modification of Diet in Renal Disease [MDRD]), or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula
• Participant agrees to not donate blood while taking lenalidomide and for 28 days after stopping lenalidomide
• Patient agrees to enroll in the lenalidomide Risk Evaluation and Mitigation Strategies (REMS) program
• Women of child-bearing potential (WOCPB) must abstain from heterosexual intercourse or agree to use a contraceptive method that is highly effective (with a failure rate of < 1% per year), preferably with low user dependency, plus one additional effective method at least 28 days before starting therapy, during the intervention period, at least 28 days after the last dose of lenalidomide and at least 4 months after the last dose of elranatamab, and agrees not to donate eggs (ova, oocytes) for reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relation to the first dose of the study intervention. * A WOCBP must have a negative highly sensitive serum pregnancy test (as required by local regulations) within 10-14 days and also within 24 hours before the first dose of the study intervention. * Nonchildbearing potential is defined as follows (by other than medical reasons): ** ≥ 45 years of age and has not had menses for > 1 year ** Patients who have been amenorrhoeic for < 2 years without a history of a hysterectomy and oophorectomy must have a follicle-stimulating hormone value in the postmenopausal range upon screening evaluation ** Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation
• Male participant agrees to contraceptive use that should be consistent with institutional guidelines regarding the methods of contraception for those participating in clinical studies * Male participants are eligible to participate if they agree to the following during the intervention period and for 1 (for lenalidomide) to 4 (for elranatamab) months after the last dose of study treatment to allow for clearance of any altered sperm: ** Refrain from donating sperm during treatment (including dose interruptions) and for 4 weeks after their last dose of lenalidomide and 4 months after the last dose of elranatamab. PLUS, either: *** Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR *** Must agree to use contraception/barrier
• ELIGIBILITY TO START PURGING THERAPY: All prior treatment-related non-hematological toxicities (defined by National Cancer Institute - Common Toxicity Criteria for Adverse Events [NCI-CTCAE], version 5) must be ≤ grade 1 at the time of enrollment except for alopecia, fatigue, and amenorrhea
• ELIGIBILITY TO START PURGING THERAPY: Peripheral neuropathy ≤ grade 2
• ELIGIBILITY TO START PURGING THERAPY: Absolute neutrophil count (ANC) ≥ 1.0 X 10^9/L
• ELIGIBILITY TO START PURGING THERAPY: Absolute lymphocyte count (ANC) ≥ 0.3 X 10^9/L
• ELIGIBILITY TO START PURGING THERAPY: Hemoglobin ≥ 8.0 g/dL
• ELIGIBILITY TO START PURGING THERAPY: Platelets ≥ 75 X 10^9/L
• ELIGIBILITY TO START DAY 1 DOSE OF EVERY CYCLE DURING MAINTENANCE THERAPY: All prior treatment- related non-hematological toxicities (defined by National Cancer Institute - Common Toxicity Criteria for Adverse Events [NCI-CTCAE], version 5) must be ≤ grade 1 at the time of enrollment except for alopecia, fatigue, and amenorrhea
• ELIGIBILITY TO START DAY 1 DOSE OF EVERY CYCLE DURING MAINTENANCE THERAPY: Peripheral neuropathy ≤ grade 2
• ELIGIBILITY TO START DAY 1 DOSE OF EVERY CYCLE DURING MAINTENANCE THERAPY: Absolute neutrophil count (ANC) ≥ 1.0 X 10^9/L
• ELIGIBILITY TO START DAY 1 DOSE OF EVERY CYCLE DURING MAINTENANCE THERAPY: Absolute lymphocyte count (ALC) ≥ 0.3 X 10^9/L
• ELIGIBILITY TO START DAY 1 DOSE OF EVERY CYCLE DURING MAINTENANCE THERAPY: Hemoglobin ≥ 8.0 g/dL
• ELIGIBILITY TO START DAY 1 DOSE OF EVERY CYCLE DURING MAINTENANCE THERAPY: Platelets ≥ 50 X 10^9/L

Exclusion Criteria

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to elranatamab or other agents used in study
• Drug interactions (Prohibited unless considered medically necessary): * At projected clinical doses, TMDD (target mediated drug disposition) of elranatamab is expected. If concomitant medication alters target expression, it can potentially impact the pharmacokinetics (PK) of elranatamab. Drugs like anti-thymocyte globulin (ATG) can deplete T-cells and can potentially impact the PK of drugs targeting CD3 * Elranatamab has been shown to increase T-cell activation and induce cytokine production (including IL-2, IL-6, IL-10, TNF-alpha and IFN-gamma). Cytokines have been shown to modulate expression of CYP enzymes and transporters, therefore, elranatamab can potentially affect CYP enzyme and transporter expression levels, and consequently modulate the clearance of concomitant medications that are substrates for these enzymes or transporters. When administering elranatamab, it is important to exercise caution with concomitant medications, especially those that are sensitive substrates of the cytochrome P450 (CYP) enzyme system and have a narrow therapeutic index. Increased exposure of CYP substrates is more likely to occur after the first dose of elranatamab on day 1 and up to 14 days after the 32 mg dose on day 4 and during and after cyctokine release syndrome (CRS). Examples of such medications include cyclosporine. During this critical window, it's imperative to closely monitor the toxicity or concentrations of these concomitant drugs. If necessary, dose adjustments for these co-administered drugs should be considered to ensure patient safety * Cytochrome P450 (CYP) enzyme system is responsible for the metabolism of a vast number of drugs. Below are examples of drugs metabolized by specific CYP enzymes that could be impacted if elranatamab alters the activity or expression of these enzymes. Exercise caution when using these drugs: ** CYP2C9 substrates: *** Warfarin *** Phenytoin *** Celecoxib *** Losartan ** CYP3A4 substrates: *** Statins: simvastatin, atorvastatin, lovastatin *** Calcineurin inhibitors: cyclosporine, tacrolimus *** Antiretroviral drugs: ritonavir, saquinavir, nelfinavir *** Benzodiazepines: diazepam, alprazolam *** Calcium channel blockers: nifedipine, verapamil, diltiazem *** Macrolide antibiotics: erythromycin, clarithromycin ** CYP2D6 substrates: *** Antipsychotics: aripiprazole, risperidone, haloperidol *** Tricyclic antidepressants: amitriptyline, nortriptyline, imipramine *** Beta-blockers: metoprolol, propranolol, carvedilol *** Codeine *** Tamoxifen ** CYP1A2 substrates: *** Theophylline *** Fluvoxamine *** Clozapine ** CYP2C19 substrates: *** Omeprazole *** Citalopram *** Diazepam * For patients on digoxin, monitor digoxin plasma levels periodically with the concomitant use of lenalidomide. Refer to lenalidomide United States Prescribing Information (USPI) for additional information
• History of progressive disease at any time before starting maintenance
• Patients with non-secretory MM (no measurable disease on electrophoresis and immunofixation). Patients with a measurable disease on PET scan or bone marrow will be eligible
• Patients with Waldenstroms macroglobulinemia
• Patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes (POEMS) syndrome
• Patients with smoldering MM (IMWG criteria)
• Patients with plasma cell leukemia
• Patients with standard-risk MM
• Patients with relapsed and/or refractory MM
• Participant must not have presence of active renal condition (infection, requirement for dialysis or any other condition that could affect participant’s safety). Participants with isolated proteinuria resulting from MM are eligible, provided they fulfill inclusion criteria
• Participant must not have current unstable liver or biliary disease defined by the presence of ascites, encephalopathy, coagulopathy, esophageal or gastric varices, persistent jaundice, or cirrhosis. Note: Stable non-cirrhotic chronic liver disease (including Gilbert’s syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if otherwise meets entry criteria
• Uncontrolled and active pulmonary disease
• Participant must not have used an investigational drug or approved systemic anti-myeloma therapy (including systemic steroids) within 14 days or five half-lives, whichever is shorter, preceding the first dose of study drug
• Participant must not have any evidence of active mucosal or internal bleeding
• Participant must not have an uncontrolled infection
• Participant must not have evidence of cardiovascular risk, including any of the following: * Evidence of current clinically significant uncontrolled arrhythmias, including clinically significant electrocardiography (ECG) abnormalities such as 2nd degree (Mobitz type II) or 3rd degree atrioventricular (AV) block * History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within three (3) months of screening * Class III or IV heart failure as defined by the New York Heart Association functional classification system * Uncontrolled hypertension (blood pressure that remains above goal despite the concurrent use of three antihypertensive drug classes)
• Participant must not have known HIV infection
• Participant must not have active hepatitis B and/or C infection
• Participant must not have invasive malignancies other than disease under study, unless the second malignancy has been medically stable for at least 2 years and, in the opinion of the principal investigators, will not affect the evaluation of the effects of clinical trial treatments on the currently targeted malignancy. Participants with curatively treated non-melanoma skin cancer may be enrolled without a 2-year restriction
• Participants must not be pregnant or lactating
• Patients with cognitive impairments and/or any serious unstable pre-existing medical condition or psychiatric disorder that can interfere with safety or with obtaining informed consent or compliance with study procedures